As METTL3 depletion can decline oncogenes’ expression and reduce CRC proliferation (Shen et al., 2020), breast cancer (Li et al., 2020c), cervical cancer (Li et al., 2020c), and liver cancer (Wang et al., 2020c), METTL3 offers an alternative therapeutic target in colorectal cancer patients with high glucose levels (Shen et al., 2020). The gene discussed is METTL3; the disease is breast carcinoma.